The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Denali Therapeutics Inc shares valued at $1,932,665 were sold by Schenkein David P on Nov 11 ’24. At $32.51 per share, Schenkein David P sold 59,441 shares. The insider’s holdings dropped to 9,220 shares worth approximately $0.22 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Schuth Alexander O. sold 15,558 shares, netting a total of over 465,286 in proceeds. Following the sale of shares at $29.91 each, the insider now holds 178,066 shares.
Before that, SATO VICKI L had sold 1,020 shares from its account. In a trade valued at $30,600, the Director traded Denali Therapeutics Inc shares for $30.00 each. Upon closing the transaction, the insider’s holdings decreased to 1,020 shares, worth approximately $2.69 million.
Analysts at Cantor Fitzgerald downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in early October. As of December 13, 2023, Citigroup has initiated its “Buy” rating for DNLI.
Analyzing DNLI Stock Performance
During the last five days, there has been a drop of approximately -14.87%. Over the course of the year, Denali Therapeutics Inc shares have jumped approximately 12.86%. Shares of the company reached a 52-week high of $33.33 on 11/11/24 and a 52-week low of $14.56 on 04/25/24. A 50-day SMA is recorded $28.00, while a 200-day SMA reached $22.58. Nevertheless, trading volume fell to 1.48 million shares from 0.77 million shares the previous day.
Support And Resistance Levels for Denali Therapeutics Inc (DNLI)
According to the 24-hour chart, there is a support level at 23.75, which, if violated, would cause prices to drop to 23.28. In the upper region, resistance lies at 24.74. The next price resistance is at 25.26. RSI (Relative Strength Index) is 36.05 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -3.32, which suggests the price will decrease in the coming days. Percent R is at 92.96%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
